secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001759425-24-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum Q3 net product sales $90.3M (+89% YoY); raises FY 2024 guidance to $330-335M
--------------------------------------------------------------------------------

- LIVMARLI net sales $59.1M; CHOLBAM/CHENODAL combined $31.2M.
- Cash & investments $293.8M vs $286.3M at Dec 2023; OpEx $103.1M incl $18M non-cash.
- PDUFA date for chenodiol in CTX set for Dec 28, 2024.
- Volixibat granted breakthrough therapy designation for PBC; interim data at AASLD.
- In-licensed PDE4D inhibitor MRM-3379 for Fragile X syndrome; Phase 2 expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000175942524000037/0001759425-24-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000175942524000037/mirm-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001759425-24-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer